- Published on
Retatrutide Certificate of Analysis (Lot 06242026): HPLC Purity, Content Assay, and FTIR Identity Data
- Authors
- Name
- Boss BioTech USA
WARNING: LABORATORY RESEARCH USE ONLY. This material is synthesized and distributed strictly for B2B development, laboratory research, and analytical studies. It is not a drug, dietary supplement, or cosmetic. Under no circumstances is this chemical compound intended for human or veterinary diagnostic or therapeutic application. All research must be conducted by qualified laboratory personnel using appropriate safety controls.
Last reviewed: 2026-08-15 · Research use only.
This page reproduces, in full, the analytical data reported on the Certificate of Analysis (CoA) for Retatrutide lot 06242026. The certificate was issued by BTLabs, an independent contract analytical laboratory in West Palm Beach, Florida, which tested a sample submitted by Boss BioTech USA. The scanned certificate is available for download below.
Every figure on this page is transcribed from that document as printed — including the specification ranges the laboratory applied, so a reviewer can check each result against its own acceptance criterion rather than taking a summary claim on trust. Where a reported value warrants explanation, the explanation is kept in a separate section (§5) so the data tables stay unedited.
For the compound's canonical chemistry — CAS number, molecular formula, receptor profile, and laboratory handling — see the full Retatrutide chemical reference. This page does not restate that chemistry; it documents one batch.
1. Download the Certificate of Analysis
Document note: the certificate is paginated page 1 of 2. The page published here is page 1, which carries the sample identification and the complete results table. Page 2 — the supporting FTIR and HPLC instrument output — is not published on this page. Requesters who need the instrument traces should ask for the complete two-page report by its report number.
2. Sample and Report Identification
Transcribed verbatim from the certificate header.
| Field | As reported on the certificate |
|---|---|
| Report number | IF-824-QSA-TR006-BTL260707-10-01 |
| Pagination | Page 1 of 2 |
| Date issued | 7/27/2026 |
| Date tested | 7/24/2026 |
| Customer | Boss Biotech |
| Testing material | Retatrutide |
| Labeled as | Retatrutide |
| Lot number | 06242026 |
| Content/potency (label claim) | 20 mg |
| Storage | R.T. (see §5.5 — this records the sample as submitted, not a handling recommendation) |
| Visual description | Small clear vial: white sample, tan label, silver crimp, pink plastic cap. |
| Manufacturer | N/A |
| Testing laboratory | BTLabs — 5601 Corporate Way, Suite 206, West Palm Beach, FL 33407 · (561) 625-0133 · info@btlabtesting.com · btlabtesting.com |
| Signatories | Andrea Castro, BS, Scientist-II · Escarlet Cabrieles, BS, Scientist-II |
Stated testing purpose (verbatim): "FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins."
3. Analytical Results as Reported
The full results table, transcribed without alteration. The Specification column is the acceptance criterion printed on the certificate itself, not a Boss BioTech USA claim.
| Test | Method | Specification (as printed) | Result (as reported) |
|---|---|---|---|
| General Appearance | USP <630> | white powder | white powder |
| Mass | USP <41> | As recorded | 86.8 mg |
| FTIR Identification and Composition Analysis | USP <197A> | Sample spectrum should confirm the content of peptide via characteristic bands | FTIR sample spectrum confirms the presence of Retatrutide with addition of excipient(s)/fillers. |
| HPLC Purity of Peptide Assay | USP <621> | ≥ 98 % | 99.8 % |
| HPLC Potency Assay | USP <621> | 90 – 110 % of 20 mg | 22.2 mg (110.9 %) |
| Peptide-to-Excipients Ratio | USP <1151> | Recommended ratios of (1:2) to (1:10) for (peptide : excipients) | 22.2 : 64.6 mg (1:2.9) |
Certificate footnote (verbatim): "The results of the CoA relate only to the item(s) tested and applied to the sample as received."
4. Scope: What This Certificate Does and Does Not Establish
Reading a CoA correctly means reading its boundaries as carefully as its numbers. Per the document's own stated testing purpose and footnote:
Covered by this certificate
- Identity of the peptide, by FTIR against characteristic absorption bands (USP <197A>).
- Chromatographic purity of the peptide assay, by HPLC (USP <621>).
- Peptide content by mass against the label claim, by HPLC (USP <621>).
- Total sample mass and the peptide-to-excipients composition ratio (USP <41>, USP <1151>).
- Visual appearance of the powder and the vial as received.
Not covered by this certificate
- Particulate matter — not assessed.
- Microbial contamination — not assessed.
- Bacterial endotoxins — not assessed.
- Sterility — not assessed; no sterility determination appears anywhere on the document.
- Mass-spectrometric identity confirmation — identity on this report was established by FTIR, not by MS. No MS data is reported.
- Lot-wide representativeness — the certificate states its results apply to the sample as received. It documents the vial submitted, not a statistically sampled survey of the lot.
On laboratory status: BTLabs is an independent contract analytical laboratory — that is, a party separate from Boss BioTech USA. Boss BioTech USA makes no claim that BTLabs holds ISO/IEC 17025 accreditation or any other formal certification, and no such accreditation is asserted on the certificate. "Independently tested" describes who ran the assay; it is not a claim of accredited or certified status.
5. Reading the Reported Values
Neutral notes on how each figure should be interpreted. No value in §2 or §3 has been adjusted.
On interpreting the HPLC purity figure itself. The 99.8 % result below is an area-percent determination, and this certificate — like nearly every certificate of its type — does not print the chromatographic conditions or integration parameters behind it. What those parameters are, why their absence limits what any purity percentage can tell you, and what to request instead are covered in what "99% purity by HPLC" means on a Certificate of Analysis, which uses this certificate as its worked example.
5.1 Purity and content are two different measurements
The 99.8 % figure and the 22.2 mg figure answer different questions and should not be conflated:
- HPLC purity (99.8 %) describes the peptide fraction: of the peptide-related material detected chromatographically, 99.8 % corresponds to Retatrutide and 0.2 % to other peptide-related species (synthesis byproducts, truncated sequences, and similar).
- HPLC content/potency (22.2 mg) describes how much Retatrutide is in the vial by mass.
A vial can be simultaneously 99.8 % pure by peptide assay and mostly non-peptide by total mass, because purity is measured across the peptide fraction rather than across the whole sample. That is exactly the case here — see §5.2.
5.2 The vial is a formulated blend, not neat peptide
Both the FTIR result and the USP <1151> ratio report the presence of excipients/fillers. The reported masses are internally consistent:
| Component | Reported mass |
|---|---|
| Retatrutide (peptide content) | 22.2 mg |
| Excipient(s)/filler(s) | 64.6 mg |
| Total sample mass | 86.8 mg |
22.2 mg + 64.6 mg = 86.8 mg, matching the mass reported under USP <41> independently. The resulting 1:2.9 peptide-to-excipients ratio falls inside the 1:2 to 1:10 window the certificate cites as recommended. The certificate does not identify which excipients were used.
5.3 The content result sits marginally above the printed acceptance range
This is stated plainly rather than rounded away or omitted. The certificate's printed acceptance criterion is 90 – 110 % of 20 mg, i.e. 18.0 – 22.0 mg. The reported result is 22.2 mg (110.9 %) — approximately 0.9 percentage points, or 0.2 mg, above the upper bound of that range. The certificate carries no pass/fail disposition column and records no deviation note against this result.
Boss BioTech USA publishes the figure exactly as the laboratory reported it. Reviewers evaluating this lot against their own incoming-material specifications should apply their own acceptance criteria to the 22.2 mg figure rather than to the 110 % ceiling printed here.
5.4 "Potency" here means content by mass
The assay named "HPLC Potency Assay" on this certificate is a quantitative content determination by mass under USP <621>. It measures how many milligrams of Retatrutide are present. It is not a measure of biological, pharmacological, or therapeutic potency, and no such determination was performed or is implied anywhere in this document.
5.5 "Storage: R.T." is a sample-intake field
The header field reading "Storage: R.T." (room temperature) records the condition under which the submitted sample was held for testing. It is not a long-term storage recommendation for lyophilized peptide reference material and should not be read as one. Handling and storage guidance for laboratory use is covered in the Retatrutide chemical reference.
5.6 Lot number and dates
The lot identifier 06242026 follows a date-style pattern (06/24/2026). The certificate records testing on 7/24/2026 and issuance on 7/27/2026. All three are transcribed as printed; the certificate does not state a manufacture date, an expiry date, or a retest date.
6. Reconciling This Certificate With the Compound Reference
The Retatrutide chemical reference describes the compound in general terms drawn from literature and databases. This certificate describes one specific batch. Where the two differ, the differences are batch-level facts, and the certificate governs for this lot:
| Point | General reference page | This certificate (lot 06242026) |
|---|---|---|
| Purity | States no compound-level purity value — purity is lot-specific and is read off the batch certificate | 99.8 % by HPLC peptide assay, against a ≥ 98 % criterion |
| Identity method | Describes HPLC purity plus MS identity confirmation as the general documentation pair | Identity established by FTIR (USP <197A>); no MS data reported |
| Physical form | Lyophilized white powder | White powder, confirmed; formulated with excipients at 1:2.9 |
| Sterility / endotoxins | Not established by this document | Explicitly outside the stated testing scope |
This is the general point a procurement reviewer should take from any CoA: a batch certificate supersedes a general product description for the lot it covers, and a general description should never be substituted for lot-specific documentation.
A B2B sourcing & verification guide — covering how to evaluate a supplier and request lot-specific documentation — is in development and will be linked here at launch.
7. Frequently Asked Questions
Q: What is the HPLC purity of Retatrutide lot 06242026? A: 99.8 %, determined by HPLC peptide assay under USP <621> against a printed specification of ≥ 98 %, per BTLabs report IF-824-QSA-TR006-BTL260707-10-01 dated 7/27/2026.
Q: How much Retatrutide is in the vial for this lot? A: The HPLC content ("potency") assay reported 22.2 mg of Retatrutide against a 20 mg label claim, which is 110.9 % of label — marginally above the 90–110 % acceptance range printed on the certificate. Total sample mass was 86.8 mg, the balance being excipients.
Q: Does the Retatrutide vial contain excipients? A: Yes. FTIR confirmed the presence of Retatrutide with added excipient(s)/fillers, and the USP <1151> ratio was reported as 22.2 : 64.6 mg, or 1:2.9 peptide to excipients — within the 1:2 to 1:10 range the certificate cites as recommended. The certificate does not name the excipients.
Q: Who tested this Retatrutide lot? A: BTLabs, an independent contract analytical laboratory in West Palm Beach, Florida, tested a sample submitted by Boss BioTech USA. No accreditation or certification status is claimed for the laboratory.
Q: Was this Retatrutide lot tested for sterility or endotoxins? A: No. The certificate states its analysis "does not provide information on particulate matter, microbial contamination or presence of endotoxins." Sterility was not assessed.
Q: Was mass spectrometry used to confirm identity on this certificate? A: No. Identity on this report was confirmed by FTIR under USP <197A>, using characteristic absorption bands. No mass-spectrometry data appears on the certificate.
Q: Does this Certificate of Analysis apply to the whole lot? A: The certificate states that its results "relate only to the item(s) tested and applied to the sample as received" — it documents the vial submitted for analysis rather than a statistical sampling of the entire lot.
8. Source Document and Methods
- Certificate of Analysis, BTLabs, report IF-824-QSA-TR006-BTL260707-10-01, page 1 of 2. Testing material: Retatrutide, lot 06242026. Date tested 7/24/2026; date issued 7/27/2026. Download the certificate.
- BTLabs, contract analytical laboratory, West Palm Beach, FL. https://btlabtesting.com
- Compendial methods cited on the certificate: USP <41> (Balances/weighing), USP <197A> (Spectrophotometric identification — infrared absorption), USP <621> (Chromatography), USP <630>, USP <1151> (Pharmaceutical dosage forms). Method chapter designations are transcribed from the certificate as printed; the United States Pharmacopeia is the authority for chapter scope (https://www.usp.org).
Related references: What is Retatrutide? (full chemical reference) · What does "99% purity by HPLC" mean on a Certificate of Analysis, and what must be stated beside it? · Retatrutide vs Tirzepatide vs Semaglutide: receptor-selectivity and chemical comparison · a B2B sourcing & verification guide is in development and will be linked here at launch.
Disclaimer: Boss BioTech USA distributes chemical compounds solely for laboratory research and analytical development. All products, including Retatrutide, are not approved for human clinical use, diagnosis, prevention, treatment, or cure of any medical condition or disease. The purchaser assumes all risks associated with the handling, testing, and use of these materials.